Silver Book Fact

Use of shingles vaccines significantly reduced disease burden

Use of a live attenuated VZV (varicella-zoster vaccine) in a randomized trial reduced the burden of illness from shingles by 61.1% and the incidence of postherpetic neuralgia (PHN) by 66.5%.

Oxman M, Levin M, Johnson G, Schmader K, et al. A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. NEJM. 2005; 352(22): 2271-84. http://www.nejm.org/doi/full/10.1056/NEJMoa051016

Reference

Title
A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults
Publication
NEJM
Publication Date
2005
Authors
Oxman M, Levin M, Johnson G, Schmader K, et al.
Volume & Issue
Volume 352, Issue 22
Pages
2271-84
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Potential savings from shingles vaccine
    Use of the shingles vaccine in immunocompetent adults ages 60 and older could save between $82 and $103 million in healthcare costs associated with the diagnosis and treatment of shingles,…  
  • Over 6 years, flu vaccine prevented ~13 million cases
    Over a 6-year period (2005 – 2011), the influenza vaccine prevented an estimated 13 million influenza cases–between 1.1 million and 5 million annually.  
  • Cost-effectiveness of flu vaccine
    Vaccination for pandemic influenza (pH1N1) prior to an outbreak produces incremental cost-effectiveness ratios for individuals without high risk conditions, ranging from $8,000 to $52,000 per quality-adjusted life year.  
  • Cost of measles much higher than vaccine
    One case of measles can cost 23 times as much as a single vaccination to prevent it.  
  • Global use of vaccine prevents death
    Compared to estimated deaths without vaccination, global use of vaccination in 2001 prevented: 61% of measles deaths; 69% of tetanus deaths; 78% of pertussis (whooping cough) deaths; 94% of diphtheria…